Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2000 Jan 18;132(2):121-4.
doi: 10.7326/0003-4819-132-2-200001180-00006.

Hepatocellular injury in a patient receiving rosiglitazone. A case report

J Al-Salman  1 , H Arjomand, D G Kemp, M Mittal
Affiliations
Case Reports

Hepatocellular injury in a patient receiving rosiglitazone. A case report

J Al-Salman et al. Ann Intern Med. .

Erratum in

  • Ann Intern Med 2000 Aug 1;133(3):237

Abstract

Background: Rosiglitazone maleate (Avandia, SmithKline Beecham, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of type 2 diabetes. It acts primarily by increasing insulin sensitivity. In controlled trials, there has been no evidence of rosiglitazone-induced hepatocellular injury.

Objective: To report a case of hepatocellular injury in a patient receiving rosiglitazone.

Design: Case report.

Setting: Community teaching hospital.

Patient: 61-year-old man receiving rosiglitazone, 4 mg/d for 2 weeks.

Intervention: Discontinuation of rosiglitazone therapy.

Measurements: Clinical evaluation and assessment of liver function test results were done daily during hospitalization and periodically after discharge. The outpatient record was also reviewed.

Results: After receiving rosiglitazone for 2 weeks, the patient presented with anorexia, vomiting, and abdominal pain. Liver function tests revealed severe hepatocellular injury. Discontinuation of rosiglitazone therapy led to rapid improvement of liver function and resolution of symptoms.

Conclusion: Rosiglitazone may be associated with hepatocellular injury. We believe that patients receiving rosiglitazone should have liver enzyme levels monitored earlier and more frequently than initially recommended.

PubMed Disclaimer

Comment in

  • Rosiglitazone and liver failure.
    Isley WL, Oki JC. Isley WL, et al. Ann Intern Med. 2000 Sep 5;133(5):393-4. doi: 10.7326/0003-4819-133-5-200009050-00022. Ann Intern Med. 2000. PMID: 10979889 No abstract available.
  • Rosiglitazone toxicity.
    Ravinuthala RS, Nori U. Ravinuthala RS, et al. Ann Intern Med. 2000 Oct 17;133(8):658. doi: 10.7326/0003-4819-133-8-200010170-00025. Ann Intern Med. 2000. PMID: 11033603 No abstract available.

Publication types

LinkOut - more resources